Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT06468228 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06468228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06468228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 27, 2024
Completion date
December 31, 2026
Enrollment
1,400 (actual)
Sites
279

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa